AbbVie (ABBV) Projected to Post Quarterly Earnings on Wednesday

AbbVie (NYSE:ABBV) is anticipated to release its Q4 2025 results before the market opens on Wednesday, February 4th. Analysts expect AbbVie to post earnings of $3.37 per share and revenue of $16.3913 billion for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 9:00 AM ET.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. During the same period in the previous year, the business posted $3.00 EPS. AbbVie’s revenue was up 9.1% on a year-over-year basis. On average, analysts expect AbbVie to post $12 EPS for the current fiscal year and $14 EPS for the next fiscal year.

AbbVie Trading Up 1.2%

Shares of NYSE:ABBV opened at $223.02 on Monday. The firm’s 50 day moving average is $224.40 and its two-hundred day moving average is $218.66. AbbVie has a 52 week low of $164.39 and a 52 week high of $244.81. The firm has a market capitalization of $394.15 billion, a P/E ratio of 168.95, a PEG ratio of 0.92 and a beta of 0.35.

Institutional Investors Weigh In On AbbVie

Large investors have recently modified their holdings of the stock. Brighton Jones LLC raised its holdings in shares of AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after acquiring an additional 3,401 shares during the period. Revolve Wealth Partners LLC grew its position in AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after purchasing an additional 3,064 shares in the last quarter. Schnieders Capital Management LLC. grew its position in AbbVie by 5.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock worth $3,056,000 after purchasing an additional 789 shares in the last quarter. Ieq Capital LLC raised its stake in AbbVie by 4.6% during the 2nd quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock valued at $22,281,000 after purchasing an additional 5,274 shares during the period. Finally, Worldquant Millennium Advisors LLC lifted its holdings in shares of AbbVie by 117.3% in the second quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock valued at $210,685,000 after purchasing an additional 612,702 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ABBV has been the topic of several analyst reports. Cantor Fitzgerald set a $250.00 target price on AbbVie and gave the company an “overweight” rating in a research report on Thursday, October 9th. Citigroup lowered their price target on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a report on Tuesday, January 27th. Erste Group Bank downgraded shares of AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. UBS Group reissued a “neutral” rating on shares of AbbVie in a research note on Tuesday, January 13th. Finally, Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $249.37.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.